July 11 (Reuters) - The European Medicines Agency (EMA) said on Tuesday it has extended its probe into Novo Nordisk's (NOVOb.CO) diabetes drugs Ozempic and weight-loss treatment Saxenda, following two reports of suicidal thoughts, to include other drugs in the same class.
Obesity affects more than one-third of adults in the U.S. Since 1980, the obesity rate among adults has more than doubled. Reversing the trend has proven difficult.
Is Europe Softening on Diet Drugs?
Eisai Gets EMA Nod For Lenvima Just Weeks After FDA Approval